Pharma BD Deal Intelligence
Takeda Pharmaceutical Company Limited / Iambic Therapeutics, Inc.
2026 · Licensing/Option · $1.7B · Complete
Takeda entered a multi-year technology and discovery collaboration with AI drug-discovery company Iambic Therapeutics, applying Iambic's generative models -- including NeuralPLexer, which predicts protein-ligand complex structures -- to a select set of high-priority Takeda small-molecule programs, initially in oncology, gastrointestinal disease and inflammation. Iambic is eligible for upfront payments, research cost contributions, technology access fees and success-based payments that could exceed US$1.7 billion in aggregate, plus royalties on net sales of any resulting products.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.
Key facts
- Announced Feb 09, 2026
- Deal value $1.7B
- Deal type Licensing/Option
- Therapeutic area Oncology, Gastroenterology, Immunology
- Key assets Access to Iambic's NeuralPLexer generative structure-prediction platform for a select set of Takeda high-priority small-molecule programs
- Mechanism AI-driven small-molecule design; NeuralPLexer protein-ligand complex structure prediction
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2026 deals · Takeda Pharmaceutical Company Limited deals · Oncology deals